NDC 63868-699

Quality Choice

Oxymetazoline Hydrochloride

Quality Choice is a Nasal Spray in the Human Otc Drug category. It is labeled and distributed by Chain Drug Marketing Association. The primary component is Oxymetazoline Hydrochloride.

Product ID63868-699_2c1074d2-e2a1-45c4-a7f1-9ce53b0206f9
NDC63868-699
Product TypeHuman Otc Drug
Proprietary NameQuality Choice
Generic NameOxymetazoline Hydrochloride
Dosage FormSpray
Route of AdministrationNASAL
Marketing Start Date2018-12-17
Marketing CategoryOTC MONOGRAPH FINAL / OTC MONOGRAPH FINAL
Application Numberpart341
Labeler NameCHAIN DRUG MARKETING ASSOCIATION
Substance NameOXYMETAZOLINE HYDROCHLORIDE
Active Ingredient Strength0 g/100mL
Pharm ClassesImidazolines [CS], Increased Sympathetic Activity [PE], Vasoconstriction [PE], Vasoconstrictor [EPC]
NDC Exclude FlagN
Listing Certified Through2023-12-31

Packaging

NDC 63868-699-22

1 BOTTLE, PUMP in 1 CARTON (63868-699-22) > 22 mL in 1 BOTTLE, PUMP
Marketing Start Date2018-12-17
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 63868-699-22 [63868069922]

Quality Choice SPRAY
Marketing CategoryOTC monograph final
Application Numberpart341
Product TypeHUMAN OTC DRUG
Marketing Start Date2018-12-17

Drug Details

Active Ingredients

IngredientStrength
OXYMETAZOLINE HYDROCHLORIDE.05 g/100mL

OpenFDA Data

SPL SET ID:d01b8fb6-1ddf-4901-bda6-ae608e94a6a4
Manufacturer
UNII
RxNorm Concept Unique ID - RxCUI
  • 1000990
    • UPC Code
  • 0635515992832

    • NDC Crossover Matching brand name "Quality Choice" or generic name "Oxymetazoline Hydrochloride"

    NDCBrand NameGeneric Name
    63868-697Quality ChoiceQuality Choice
    63868-699Quality ChoiceQuality Choice
    63868-347Quality ChoiceQuality Choice
    63868-530Quality ChoiceQuality Choice
    10202-3047 Select Nasaloxymetazoline hydrochloride
    10202-8497 Select Original NasalOxymetazoline Hydrochloride
    11523-1159AfrinOxymetazoline hydrochloride
    11523-0073Afrin Allergy Sinus Nasaloxymetazoline hydrochloride
    11523-1160Afrin No Drip Nightoxymetazoline hydrochloride
    11523-0034Afrin NoDrip Allergy Sinus Nightoxymetazoline hydrochloride
    0363-0304Anefrin Nasaloxymetazoline hydrochloride
    0113-7388basic care nasalOxymetazoline Hydrochloride
    0113-7494basic care no drip nasalOxymetazoline hydrochloride
    11523-0091Children Afrin Extra Moisturizing Stuffy Nose Pump MistOxymetazoline hydrochloride
    11523-0090Children Afrin No Drip Extra Moisturizing Stuffy Nose Pump MistOxymetazoline hydrochloride
    0573-1191DRISTAN 12 HRoxymetazoline hydrochloride
    0113-0304Good Sense Nasaloxymetazoline hydrochloride
    0113-0817Good Sense Nasaloxymetazoline hydrochloride
    0113-2304Nasaloxymetazoline hydrochloride
    0904-5711NasalOxymetazoline Hydrochloride
    0536-5005Nasal ReliefOxymetazoline Hydrochloride
    0363-7007No Drip Anefrin NasalOXYMETAZOLINE HYDROCHLORIDE
    0023-5300RHOFADEOxymetazoline Hydrochloride
    0363-2021Severe AnefrinOXYMETAZOLINE HYDROCHLORIDE
    0363-7009Severe Sinus Relief Mistoxymetazoline hydrochloride
    10237-464Zicam Extreme Congestion Reliefoxymetazoline hydrochloride
    10237-471Zicam Intense Sinus Reliefoxymetazoline hydrochloride

    Trademark Results [Quality Choice]

    Mark Image

    Registration | Serial
    Company
    Trademark
    Application Date
    QUALITY CHOICE
    QUALITY CHOICE
    77326160 3440520 Live/Registered
    CHAIN DRUG MARKETING ASSOCIATION, INC.
    2007-11-09
    QUALITY CHOICE
    QUALITY CHOICE
    77326104 3440519 Live/Registered
    CHAIN DRUG MARKETING ASSOCIATION, INC.
    2007-11-09
    QUALITY CHOICE
    QUALITY CHOICE
    76571887 2964690 Live/Registered
    CHAIN DRUG MARKETING ASSOCIATION, INC.
    2004-01-26
    QUALITY CHOICE
    QUALITY CHOICE
    74561878 2144847 Live/Registered
    CHAIN DRUG MARKETING ASSOCIATION, INC.
    1994-08-17
    QUALITY CHOICE
    QUALITY CHOICE
    74035467 not registered Dead/Abandoned
    Manhattan Life Insurance Co., The
    1990-03-05
    © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.